Literature DB >> 33707937

Refocusing on the Primary Prevention of Heart Failure.

Lua A Jafari1,2, Rachel M Suen1,2, Sadiya S Khan1,2,3.   

Abstract

PURPOSE OF REVIEW: The burden of heart failure (HF) is a significant national and global public health problem, with prevalence rates on the rise. Given the significant morbidity, mortality, and healthcare costs attributable to HF, it is of utmost importance to utilize preventive strategies to prevent the development of HF. Therefore, we sought to address how a multi-modal risk assessment approach can be used to stratify patients for HF risk and guide implementation of therapeutic strategies to prevent HF. RECENT
FINDINGS: New externally validated, multivariate prediction models for incident HF can be applied in the general population and may be used to aide clinicians in assessing individualized HF risk and screening for HF. Recent clinical trial data suggest a natriuretic peptide biomarker-based screening approach coupled with team-based cardiovascular care to focus on optimization of guideline-directed medical therapy may help prevent new-onset HF. However, widespread implementation of clinical risk scores and/or biomarkers is needed.
SUMMARY: In addition to promoting a heart healthy lifestyle, prevention and management of modifiable risk factors, including intensive blood pressure lowering and use of sodium-glucose cotransporter-2 inhibitors, can prevent incident HF.

Entities:  

Keywords:  Diabetes; Heart failure; Hypertension; Preention

Year:  2020        PMID: 33707937      PMCID: PMC7943057          DOI: 10.1007/s11936-020-00811-3

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  114 in total

1.  Dose-response relationship of total and leisure time physical activity to risk of heart failure: a prospective cohort study.

Authors:  Kasper Andersen; Daniela Mariosa; Hans-Olov Adami; Claes Held; Erik Ingelsson; Ylva Trolle Lagerros; Olof Nyrén; Weimin Ye; Rino Bellocco; Johan Sundström
Journal:  Circ Heart Fail       Date:  2014-09-02       Impact factor: 8.790

2.  Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation.

Authors:  Ambarish Pandey; Sunghee Kim; Curtiss Moore; Laine Thomas; Bernard Gersh; Larry A Allen; Peter R Kowey; Kenneth W Mahaffey; Elaine Hylek; Eric D Peterson; Jonathan P Piccini; Gregg C Fonarow
Journal:  JACC Heart Fail       Date:  2017-01       Impact factor: 12.035

3.  Community Screening for Nonischemic Cardiomyopathy in Asymptomatic Subjects ≥65 Years With Stage B Heart Failure.

Authors:  Hong Yang; Ying Wang; Mark Nolan; Kazuaki Negishi; Peter M Okin; Thomas H Marwick
Journal:  Am J Cardiol       Date:  2016-04-06       Impact factor: 2.778

4.  Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

Review 5.  Epidemiology and aetiology of heart failure.

Authors:  Boback Ziaeian; Gregg C Fonarow
Journal:  Nat Rev Cardiol       Date:  2016-03-03       Impact factor: 32.419

6.  Association of electrocardiogram abnormalities and incident heart failure events.

Authors:  Baris Gencer; Javed Butler; Douglas C Bauer; Reto Auer; Andreas Kalogeropoulos; Pedro Marques-Vidal; William B Applegate; Suzanne Satterfield; Tamara Harris; Anne Newman; Eric Vittinghoff; Nicolas Rodondi
Journal:  Am Heart J       Date:  2014-04-05       Impact factor: 4.749

7.  An investigation of coronary heart disease in families. The Framingham offspring study.

Authors:  W B Kannel; M Feinleib; P M McNamara; R J Garrison; W P Castelli
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

8.  Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

Authors:  David Fitchett; Silvio E Inzucchi; Christopher P Cannon; Darren K McGuire; Benjamin M Scirica; Odd Erik Johansen; Steven Sambevski; Stefan Kaspers; Egon Pfarr; Jyothis T George; Bernard Zinman
Journal:  Circulation       Date:  2019-03-12       Impact factor: 29.690

9.  Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction.

Authors:  Rajalakshmi Santhanakrishnan; Na Wang; Martin G Larson; Jared W Magnani; David D McManus; Steven A Lubitz; Patrick T Ellinor; Susan Cheng; Ramachandran S Vasan; Douglas S Lee; Thomas J Wang; Daniel Levy; Emelia J Benjamin; Jennifer E Ho
Journal:  Circulation       Date:  2016-01-08       Impact factor: 29.690

10.  Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies.

Authors:  James S Ware; Jian Li; Erica Mazaika; Christopher M Yasso; Tiffany DeSouza; Thomas P Cappola; Emily J Tsai; Denise Hilfiker-Kleiner; Chizuko A Kamiya; Francesco Mazzarotto; Stuart A Cook; Indrani Halder; Sanjay K Prasad; Jessica Pisarcik; Karen Hanley-Yanez; Rami Alharethi; Julie Damp; Eileen Hsich; Uri Elkayam; Richard Sheppard; Angela Kealey; Jeffrey Alexis; Gautam Ramani; Jordan Safirstein; John Boehmer; Daniel F Pauly; Ilan S Wittstein; Vinay Thohan; Mark J Zucker; Peter Liu; John Gorcsan; Dennis M McNamara; Christine E Seidman; Jonathan G Seidman; Zoltan Arany
Journal:  N Engl J Med       Date:  2016-01-06       Impact factor: 91.245

View more
  2 in total

1.  Lifetime Risk of Heart Failure Among Participants in the Framingham Study.

Authors:  Ramachandran S Vasan; Danielle M Enserro; Alexa S Beiser; Vanessa Xanthakis
Journal:  J Am Coll Cardiol       Date:  2022-01-25       Impact factor: 24.094

Review 2.  The sympathies of the body: functional organization and neuronal differentiation in the peripheral sympathetic nervous system.

Authors:  Uwe Ernsberger; Thomas Deller; Hermann Rohrer
Journal:  Cell Tissue Res       Date:  2021-11-10       Impact factor: 5.249

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.